Sompraz%2525252525252525252525252525252525252525252525252525252520hp

## Sompraz hp ### Overview Sompraz hp is a combination product containing pantoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* (*H. pylori*). Pantoprazole is a proton pump inhibitor (PPI), while amoxicillin and clarithromycin are antibiotics. ### Primary Indications * Eradication of *Helicobacter pylori* (*H. pylori*) infection in patients with peptic ulcer disease. ### Adult Dosing The typical regimen is one capsule (containing pantoprazole 40 mg, amoxicillin 500 mg, and clarithromycin 500 mg) taken orally twice daily for 7 to 14 days. The exact duration of therapy may vary based on local resistance patterns and clinical guidelines. ### Pediatric Dosing Specific dosing for pediatric patients is not established for this fixed-combination product. Dosing would need to be calculated based on individual components and age/weight, following established pediatric guidelines for *H. pylori* eradication, which often involve different formulations and dosages. ### Dose Adjustments No dose adjustments are typically required for renal or hepatic impairment for the fixed-combination product as a whole, but caution is advised. Individual components may require adjustment: * **Pantoprazole:** No specific dose adjustment for mild to moderate hepatic impairment. Severe impairment may require a reduced dose (e.g., 20 mg daily). Renal impairment does not typically require dose adjustment. * **Amoxicillin:** Dose adjustment may be needed in severe renal impairment. * **Clarithromycin:** Dose adjustment is recommended in patients with moderate to severe renal impairment (CrCl < 30 mL/min), reducing the dose by half. ### Contraindications * Hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or other macrolides or penicillins. * History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use. * Concomitant use with rifabutin, cisapride, domperidone, pimozide, or other drugs that are substrates of CYP3A4 with a narrow therapeutic index. ### Adverse Effects Common adverse effects include diarrhea, nausea, abdominal pain, headache, dizziness, rash, and taste disturbances. Serious adverse effects may include severe allergic reactions, *Clostridioides difficile*-associated diarrhea, liver dysfunction, and QT prolongation (clarithromycin). ### Key Drug Interactions * **CYP3A4 Substrates:** Clarithromycin is a moderate inhibitor of CYP3A4. Concomitant use with drugs metabolized by CYP3A4 (e.g., warfarin, certain statins, benzodiazepines, cyclosporine, tacrolimus, certain antivirals) can increase their plasma concentrations and risk of toxicity. * **Warfarin:** Increased INR and bleeding risk. * **Digoxin:** Increased digoxin levels. * **Proton Pump Inhibitors:** May affect absorption of other drugs requiring acidic environment (e.g., ketoconazole, itraconazole, certain HIV protease inhibitors). * **Amoxicillin:** Can decrease the efficacy of oral contraceptives. ### Monitoring * Assess for signs and symptoms of *H. pylori* eradication post-therapy (e.g., urea breath test, stool antigen test). * Monitor for adverse effects, particularly diarrhea, rash, and signs of liver dysfunction. * Monitor INR in patients receiving warfarin. * Monitor electrolytes and ECG if risk factors for QT prolongation are present. ### Clinical Pearls * This combination product simplifies the regimen for *H. pylori* eradication. * Ensure patients complete the full course of therapy, even if symptoms improve. * Advise patients to report any severe diarrhea or allergic reactions immediately. * Clarify local antibiotic resistance patterns for *H. pylori* to guide optimal therapy duration and choice. *** **Disclaimer:** This information is intended for healthcare professionals. Always verify current prescribing information and consult relevant clinical guidelines before making treatment decisions. Dosing and recommendations may vary based on individual patient factors and local protocols.